Be The Match BioTherapies
Colleen Kelly Taber is a seasoned operations and administrative professional with diverse experience across various organizations. Currently serving as a Donor Operations Specialist at NMDP BioTherapies since March 2022, Colleen has previously held roles including Administrator at Kern County Farm Bureau, where responsibilities involved managing office operations and supporting board communications. Colleen's background also includes significant leadership and coordination positions at EurAupair and the Center for Land-Based Learning, focused on program management, community liaison, and empowering individuals through education. Colleen's experience further encompasses office management and administrative support in educational and corporate settings. Academic credentials include studies from the University of Phoenix, California Polytechnic State University-San Luis Obispo, and Cuesta College.
This person is not in any offices
Be The Match BioTherapies
Be The Match BioTherapies® partners with cell and gene therapy companies to save lives through autologous and allogeneic cellular therapy. We are the only cell and gene therapy solutions provider with customizable services to support the entire end-to-end cell therapy supply chain. As part of the National Marrow Donor Program®(NMDP)/Be The Match®, Be The Match BioTherapies has sourced, collected and delivered cells from more than 100,000 volunteer allogeneic donors around the world for time-critical cellular therapies. We have extensive experience providing cellular source material consented for research, clinical and commercial use. Throughout the past 35+ years, Be The Match BioTherapies has developed and continually enhanced their cell collection network and proven cell therapy supply chain infrastructure. The teams are responsible for more than 6,500 time-sensitive cell therapy shipments per year. Through the CIBMTR® (Center for International Blood and Marrow Transplant Research®), Be The Match BioTherapies provides long-term follow-up tracking for the first two FDA-approved CAR-T therapies. We ask that you please review and follow our Community Guidelines to ensure responsible and respectful conversations: http://bit.ly/2Apu7Ja